Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 76,464 shares of the biopharmaceutical company's stock after selling 4,104 shares during the quarter. Ensign Peak Advisors Inc owned 0.06% of Alnylam Pharmaceuticals worth $17,993,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Capital World Investors raised its position in Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after buying an additional 92,101 shares during the last quarter. Vanguard Group Inc. raised its position in Alnylam Pharmaceuticals by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after buying an additional 98,303 shares during the last quarter. Capital Research Global Investors raised its position in Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. raised its position in Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after buying an additional 1,245,195 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY traded up $1.91 on Friday, hitting $285.31. The company had a trading volume of 1,193,496 shares, compared to its average volume of 911,900. The company has a market capitalization of $37.20 billion, a PE ratio of -131.48 and a beta of 0.17. The company's fifty day moving average price is $253.73 and its 200-day moving average price is $253.58. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 12-month low of $146.79 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the previous year, the business posted ($0.16) earnings per share. The firm's revenue was up 20.2% compared to the same quarter last year. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research report on Friday, March 21st. Scotiabank lifted their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a report on Monday, March 31st. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. HC Wainwright reaffirmed a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Finally, Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 target price for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have given a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $319.17.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares of the company's stock, valued at $3,240,344.36. The trade was a 10.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,017,271.63. This trade represents a 11.44% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.